High Incidence of Respiratory Syncytial Virus in Children with Community-Acquired Pneumonia from a City in the Brazilian Pre-Amazon Region

Viruses. 2023 May 31;15(6):1306. doi: 10.3390/v15061306.

Abstract

Introduction: Although fewer children have been affected by the severe form of the coronavirus disease 2019 (COVID-19), community-acquired pneumonia (CAP) continues to be the leading global cause of child hospitalizations and deaths.

Aim: This study investigated the incidence of respiratory syncytial virus (RSV) as well its subtypes (RSV A and B), adenovirus (ADV), rhinovirus (HRV), metapneumovirus (HMPV), coronavirus (NL63, OC43, 229E and HKU1), parainfluenza virus subtypes (PI1, PI2 and PI3), bocavirus and influenza A and B viruses (FluA and FluB) in children diagnosed with CAP during the COVID-19 pandemic.

Methods: A total of 200 children with clinically confirmed CAP were initially recruited, of whom 107 had negative qPCR results for SARS-CoV-2 and were included in this study. Viral subtypes were identified using a real-time polymerase chain reaction in the nasopharyngeal swab samples.

Results: Viruses were identified in 69.2% of the patients. RSV infections were the most frequently identified (65.4%), with type RSV B being the most prevalent (63.5%). In addition, HCoV 229E and HRV were detected in 6.5% and 3.7% of the patients, respectively. RSV type B was associated with severe acute respiratory infection (ARI) and a younger age (less than 24 months).

Conclusions: New strategies for preventing and treating viral respiratory infections, particularly RSV infections, are necessary.

Keywords: child; clinical epidemiology; respiratory tract infections.

MeSH terms

  • Brazil / epidemiology
  • COVID-19* / epidemiology
  • Child
  • Child, Preschool
  • Community-Acquired Infections* / epidemiology
  • Humans
  • Incidence
  • Infant
  • Pandemics
  • Pneumonia* / epidemiology
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus, Human* / genetics
  • Respiratory Tract Infections*
  • SARS-CoV-2

Grants and funding

This research received no external funding.